Navigation Links
3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
Date:2/29/2012

LONDON, February 29, 2012 /PRNewswire/ --

In the latest development in an ongoing global legal dispute, 3M Company (3M) has withdrawn a lawsuit it filed in a New York court against Harvey Boulter, the CEO of investment fund manager Porton Group.

The termination of 3M's lawsuit in New York follows a decision earlier this month by a Washington DC federal judge ruling that 3M's "blackmail" claim against the Porton Group's Washington DC attorney was invalid.

3M's withdrawal of the case in New York also comes in the wake of Porton's victory in the High Court in London last November, where 3M was held liable for damages for breach of its contractual obligations over its failure to develop a test to track MRSA in hospitals after buying the base technology from a consortium led by Porton.

Porton Group CEO, Harvey Boulter, said: "I am delighted that 3M has withdrawn its New York lawsuit. 3M made unfounded accusations in the US designed to deflect attention from the case in the UK, where 3M was held liable for breach of contract.

"3M's spurious 'blackmail' claims had absolutely no merit. I am pleased that the New York case has been closed on this sham of a dispute."

The decision coincides with the departure of Sir George Buckley as President and CEO of 3M last week (24 February). The legal wrangle was ignited publically when 3M falsely alleged that Mr Boulter had threatened, after a meeting with the then UK Defence Secretary Liam Fox, to use political contacts to have Sir George stripped of his knighthood unless 3M paid Porton $30 million to settle the contract dispute.

Notes to Editors:

For further information please contact Eben Black on +44-7968-559-198 or eben.black@dlapiper.com or Anna Brown on +44-7834-570-464 or anna.brown@dlapiper.com.

This release supersedes that issued on the same subject on February 23.



'/>"/>
SOURCE Porton Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WHO Withdraws Notice of Concern for Mylans Matrix Unit
2. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
3. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
4. US Patent Office Rejects 95% of Verathon Claims in Patent Case With Aircraft Medical
5. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
6. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
7. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
8. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
9. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
10. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
11. False Claims by Supporters Swirl Around Hayashi Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in ... the patient's condition, treatment may be offered IV, intrathecal or with a combination. , ... dementia, and the incidence continues to increase as individuals live longer. There is no ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... data insights, today announced that the launch of a new clinical ... data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service ...
(Date:6/28/2020)... ... 26, 2020 , ... The Security Industry Association ... opposition to the recently introduced bicameral Facial Recognition and Biometric Technology Moratorium ... use of nearly all biometric and related image analytics technologies, incorrectly labeling all ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., ... presented June 22-24 during the American Association for Cancer Research Virtual meeting. One ... the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
Breaking Biology Technology:
(Date:7/2/2020)... ... July 02, 2020 , ... Dutch ... the use of its revolutionary NEXTGENPCR endpoint thermocycler to test for SARS-CoV-2 ... The article, titled "Ultra-fast one-step RT-PCR protocol for the detection of SARS-CoV-2," ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
(Date:6/23/2020)... ... , ... In its June 22 online post, business and technology news platform ... Ph.D., founder and director of stem cell biotechnology company Asymmetrex . Superb Crew ... starting July 5 it would begin offering free tissue stem cell counting ...
Breaking Biology News(10 mins):